Showing 1 - 10 of 833
Do intellectual property (IP) rights on existing technologies hinder subsequent innovation? Using newly-collected data on the sequencing of the human genome by the public Human Genome Project and the private firm Celera, this paper estimates the impact of Celera's gene-level IP on subsequent...
Persistent link: https://www.econbiz.de/10012462442
This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...
Persistent link: https://www.econbiz.de/10012466796
Biologics accounted for roughly $145 billion in spending in 2018 (IQVIA, 2019). They are also the fastest growing segment of the pharmaceutical industry. The Biological Price Competition and Innovation Act (BPCIA) of 2010 created an abbreviated pathway for biosimilar products to promote price...
Persistent link: https://www.econbiz.de/10012496071
Pharmacogenomics, or the application of genetic testing to guide drug selection and/or dosing, is often cited as integral to the vision of how precision medicine can be integrated into routine clinical practice. Yet despite a growing base of scientific discovery on genetic variation that...
Persistent link: https://www.econbiz.de/10012453580
This paper revisits Peltzman (1973) in light of two recent opportunities to quantitatively assess tradeoffs in drug regulation. First, reduced regulatory barriers to drug manufacturing associated with the 2017 reauthorization of Generic Drug User Fee Amendments were followed by significantly...
Persistent link: https://www.econbiz.de/10012794602
We study the Medicare Part D prescription drug insurance program as a bellwether for designs of private, non …-mandatory health insurance markets that control adverse selection and assure adequate access and coverage. We model Part D enrollment …
Persistent link: https://www.econbiz.de/10012463257
Medicare enrollees with private Rx insurance is about 9% lower than the mean age of drugs used by Medicare enrollees without … either private or public Rx insurance …
Persistent link: https://www.econbiz.de/10012469718
Both under- and over-treatment of communicable diseases are public bads. But efforts to decrease one run the risk of increasing the other. Using rich experimental data on household treatment-seeking behavior in Kenya, we study the implications of this tradeoff for subsidizing life-saving...
Persistent link: https://www.econbiz.de/10012460716
There is significant interest in understanding the labor market consequences of the opioid epidemic, but little is known about how opioid use impacts on-the-job productivity. We analyze the impact of opioid initiation in the emergency department (ED) on workforce outcomes in the Military using...
Persistent link: https://www.econbiz.de/10013334329
Many researchers in both economics departments and business schools recently have become interested in examining how much of an effect human resource decisions and policies have on firm performance. This paper surveys the literature on unionism and productivity and discusses its implications for...
Persistent link: https://www.econbiz.de/10012476316